Free Trial

Corcept Therapeutics (CORT) Earnings Date, Estimates & Call Transcripts

Corcept Therapeutics logo
$56.09 +1.79 (+3.30%)
(As of 11/20/2024 ET)

Corcept Therapeutics Latest Earnings Summary

Upcoming Q4
Earnings Date
Feb. 20Estimated
Actual EPS
(Oct. 30)
$0.41 Beat By $0.14
Consensus EPS
(Oct. 30)
$0.27

Corcept Therapeutics issued Q3 2024 earnings on October 30, 2024, reporting an EPS of $0.41, which beat analysts' consensus estimates of $0.27 by $0.14. Quarterly revenue rose 47.7% year-over-year to $182.55 million, above analyst estimates of $171.97 million. With a trailing EPS of $1.26 and a P/E Ratio of 44.52, Corcept Therapeutics' earnings are expected to grow 39.69% next year, from $1.31 to $1.83 per share.

CORT Upcoming Earnings

Corcept Therapeutics' next earnings date is estimated for Thursday, February 20, 2025, based off prior year's reporting schedules.

Get Corcept Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Corcept Therapeutics and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

CORT Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

CORT Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Corcept Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20244-$0.02$0.31$0.15 
Q2 20244$0.20$0.36$0.25 
Q3 20244$0.20$0.38$0.28 
Q4 20244$0.26$0.46$0.36 
FY 202416$0.64$1.51$1.04 
Q1 20252$0.30$0.35$0.33 
Q2 20252$0.33$0.41$0.37 
Q3 20252$0.39$0.46$0.43 
Q4 20252$0.47$0.48$0.48 
FY 20258$1.49$1.70$1.60 
Q1 20261$0.45$0.45$0.45 
Q2 20261$0.51$0.51$0.51 
Q3 20261$0.57$0.57$0.57 

Corcept Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks
2/20/2025
(Estimated)
------- 
10/30/2024Q3 2024$0.27$0.41+$0.14$0.41$171.97M$182.55M    
7/29/2024Q2 2024$0.23$0.32+$0.09$0.32$155.14M$163.80M      
5/1/2024Q1 2024$0.21$0.25+$0.04$0.25$141.19M$146.80M      
2/15/2024Q4 2023$0.25$0.28+$0.03$0.28$129.27M$135.41M      
11/1/2023Q3 2023$0.22$0.28+$0.06$0.28$119.71M$123.60M      
8/2/2023Q2 2023$0.15$0.25+$0.10$0.25$109.60M$117.72M      
5/3/2023Q1 2023$0.20$0.14 -$0.06$0.14$104.91M$105.70M      
2/28/2023Q4 2022$0.23$0.14 -$0.09$0.14$106.93M$103.06M      

Corcept Therapeutics Earnings - Frequently Asked Questions

Corcept Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 20th, 2025 based off last year's report dates. Learn more on CORT's earnings history.

Corcept Therapeutics updated its FY 2024 earnings guidance on Wednesday, October, 30th. The company issued revenue guidance of $675.0 million-$700.0 million, compared to the consensus revenue estimate of $661.1 million.

In the previous quarter, Corcept Therapeutics (NASDAQ:CORT) reported $0.41 earnings per share (EPS) to beat the analysts' consensus estimate of $0.27 by $0.14. Learn more on analysts' earnings estimate vs. CORT's actual earnings.

The conference call for Corcept Therapeutics's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Corcept Therapeutics's latest earnings report can be read online.
Read Transcript

Corcept Therapeutics (NASDAQ:CORT) has a recorded annual revenue of $482.38 million.

Corcept Therapeutics (NASDAQ:CORT) has a recorded net income of $106.14 million. CORT has generated $1.26 earnings per share over the last four quarters.

Corcept Therapeutics (NASDAQ:CORT) has a trailing price-to-earnings ratio of 44.52 and a forward price-to-earnings ratio of 42.82.

Corcept Therapeutics's earnings are expected to grow from $1.31 per share to $1.83 per share in the next year, which is a 39.69% increase.

`

More Earnings Resources from MarketBeat



This page (NASDAQ:CORT) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners